Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

Multiple Myeloma Lab - Prof Kwee Yong

• Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr L M, Fieles W E, Tunstead J, Germaschewski F, Mayes P, Craigen J,ÌýYong KL. (2016) Evaluation of B Cell Maturation Antigen as a Target for Antibody Drug Conjugate Mediated Cytotoxicity in Multiple Myeloma.ÌýBritish Journal of Haematology, 17 June 2016. doi:10.1111/bjh.14145.
  Ìý
• Kassen D, Lath D, Lach A, Evans H, Chantry A, Rabin N, Croucher P, andÌýYong KL. (2016) Myeloma Impairs Mature Osteoblast Function but Causes Early Expansion of Osteo-Progenitors: Temporal Changes in Bone Physiology and Gene Expression in the KMS12BM Model.ÌýBritish Journal of HaematologyÌý172:64-79
  Ìý
• Smith, Dean, David Mann, andÌýKwee Yong.Ìý(2016) Cyclin D Type Does Not Influence Cell Cycle Response to DNA Damage Caused by Ionizing Radiation in Multiple Myeloma Tumours.ÌýBritish Journal of HaematologyÌý173, no. 5 (June 2016): 693–704. doi:10.1111/bjh.13982.
  Ìý
• Sive, Jonathan I., Andrew Feber, Dean Smith, John Quinn, Stephan Beck, andÌýKwee Yong. (2016) ‘Global Hypomethylation in Myeloma Is Associated with Poor Prognosis’.ÌýBritish Journal of HaematologyÌý172, no. 3 (February 2016): 473–75. doi:10.1111/bjh.13506.
  Ìý
• Sive, Jonathan I., Andrew Feber, Dean Smith, John Quinn, Stephan Beck, andÌýKwee Yong. (2016) ‘Global Hypomethylation in Myeloma Is Associated with Poor Prognosis’.ÌýBritish Journal of HaematologyÌý172, no. 3 (February 2016): 473–75. doi:10.1111/bjh.13506.
  Ìý
• Smith D, Armenteros E, Percy L, Kumar M, Lach A, Herledan G, Stubbs M, Downward J, andÌýYong KL. (2015) RAS Mutation Status and Bortezomib Therapy for Relapsed Multiple Myeloma.ÌýBritish Journal of HaematologyÌý169, no. 6 (June 2015): 905–8. doi:10.1111/bjh.13258.
  Ìý
• Kassen D, Moore S, Percy L, Herledan G, Bounds D, Rodriguez-Justo M,ÌýYong KL. (2014) The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.ÌýBritish Journal of HaematologyÌý167: 194-206
  Ìý
• **Rabin N, Percy L, Khan I, Quinn J, D’Sa S, Yong KL (2012) Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. Br J Haematol 2012 June 19 (epub)Ìý
  Ìý
• **Percy LA, Moore SE, Qian W, Dorman J, Rabin N, Watts M, Linch DC, Yong KL. (2012) Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma. Br J Haematol; 157:1365
  Ìý
• Stengel C, Cheung CW, Quinn J,ÌýYong K, and Khwaja A. (2012) Optimal Induction of Myeloma Cell Death Requires Dual Blockade of Phosphoinositide 3-kinase and mTOR Signalling and Is Determined by Translocation Subtype.ÌýLeukemiaÌý26:1761-1770.
  Ìý
• Glassford J, Kassen D, Quinn J, Stengel C, Kallinikou K, Khwaja A,ÌýYong KLÌý(2011). Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations.ÌýBlood Cancer JournalÌýe50 doi:10.1038/bcj.2011.44
  Ìý
• Quinn, J., Glassford, J., Percy, L., Munson, P., Marafioti, T., Rodriguez-justo, M.,ÌýYong, K. (2011). APRIL promotes cell cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status.ÌýBloodÌý117:890-901
  Ìý
• Quinn, J., Percy, L., Glassford, J., Somana, K., Rodriguez-justo, M.,ÌýYong, K. (2010). CD20-positive multiple myeloma - differential expression of cyclins D1 and D2 suggests a heterogeneous disease.ÌýBritish Journal of HaematologyÌý149(1), 156-159
  Ìý
• Kyriakou, C., Rabin, N., Pizzey, A., Nathwani, A.,ÌýYong, K. (2008). Short term homing of human bone marrow derived mesenchymal stem cells (hMSCs) in a xenogeneic animal model is influenced by animal age and is increased by enforced expression of CXCR4.ÌýHaematologicaÌý93(10), 1457-1465
  Ìý
• Glassford, J., Rabin, N., Lam, E. W.,ÌýYong, K. L. (2007). Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.ÌýBritish Journal of HaematologyÌý139(2), 243-254Ìý
  Ìý
• Rabin, N., Kyriakou, C., Coulton, L., Gallagher, O. M., Buckle, C., Benjamin, R., Singh, N., Glassford, J., Otsuki, T., Nathwani, A. C., Croucher, P. I.,ÌýYong, K. L.Ìý(2007). A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer.ÌýLeukemiaÌý21:2181-2191